Clinical Trials Logo

Filter by:
NCT ID: NCT03164070 Enrolling by invitation - Osteoarthritis Clinical Trials

Study of the Laboratory-based Evaluation of the Degrees of Activity of Osteoarthritis

Start date: July 1, 2016
Phase: N/A
Study type: Observational

This study evaluates laboratory-based method to estimate the degrees of activity of medium and large joint osteoarthritis.

NCT ID: NCT03164044 Enrolling by invitation - Drug Allergy Clinical Trials

Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Start date: January 3, 2017
Phase: N/A
Study type: Observational

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

NCT ID: NCT03114631 Enrolling by invitation - Clinical trials for Pancreatic Neoplasms

Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer

Start date: January 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer

NCT ID: NCT03072576 Recruiting - Clinical trials for Tuberculosis, Pulmonary

Accuracy and Feasibility of Xpert Ultra

Start date: March 2016
Phase: N/A
Study type: Observational

Consenting adults presenting with signs and symptoms compatible with pulmonary tuberculosis will be interviewed for demographic and medical information, and then will be asked to provide 3-4 expectorated sputum specimens. In the study laboratory, sputa will be tested using conventional and investigational diagnostic tests for tuberculosis and rifampin resistance.

NCT ID: NCT03062644 Recruiting - Acute Pain Clinical Trials

Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.

STARDOM2
Start date: April 5, 2017
Phase: Phase 3
Study type: Interventional

The MR308-3502 study is a multicenter double-blind, randomised, placebo- and active comparator-controlled study in female subjects to evaluate the efficacy and safety of MR308 with acute pain after TAH or STAH (total or subtotal abdominal hysterectomy).

NCT ID: NCT03045302 Recruiting - Acromegaly Clinical Trials

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

DOPAACRO 002
Start date: January 26, 2017
Phase: Phase 2
Study type: Interventional

The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.

NCT ID: NCT03031470 Active, not recruiting - Clinical trials for Early Allograft Dysfunction

Efficacy and Safety Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Orthotopic Liver Transplantation Patients

Start date: March 2015
Phase: Phase 2
Study type: Interventional

Liver transplantation is currently the treatment of choice for end-stage liver cirrhosis of different origin, as well as for a number of inborn metabolism disorders and liver tumors. The need to perform a liver transplantation is high and amounts to 10 - 20 patients per 1 million population per year. Experimental and clinical evidence demonstrate the harmful short and long-term effects of ischemia-reperfusion injury (IRI) of the donor organ on the outcome of the intervention performed. Severe manifestations of IRI of the liver transplant (LT) is one of the main reasons for the increased length of hospitalization, the high cost of treating patients during the post- surgery period, the development of persistent early allograft dysfunction or loss, frequent crises of acute rejection, acute renal and multiple organ failure, and mortality of the operated patients. This pilot clinical study is designed to evaluate the efficacy and safety of Reparixin, which is a new, potent and specific inhibitor of chemokine CXCL8 (Interleukin-8), as an agent to prevent early allograft dysfunction caused by ischemia-reperfusion injury in patients undergoing orthotopic liver transplantation.

NCT ID: NCT02968173 Active, not recruiting - Clinical trials for Respiratory Syncytial Virus (RSV)

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus

Synagis Russia
Start date: November 9, 2016
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, prospective, multicenter, open-label, non-controlled study to assess the safety and effectiveness of immunoprophylaxis with the intramuscular (IM) administration of the liquid formulation of palivizumab for the prevention of RSV hospitalizations in infants at high risk (infants born at less than or equal to 35 weeks gestational age and less than or equal to 6 months of age at enrollment; or infants less than or equal to 24 months of age with a diagnosis of chronic lung disease [CLD] of prematurity requiring on-going medical treatment within the previous 6 months or infants less than or equal to 24 months of age with hemodynamically significant congenital heart disease [CHD]).

NCT ID: NCT02966457 Recruiting - Clinical trials for Hematological Infection

A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)

DEHAM
Start date: January 2017
Phase: Phase 4
Study type: Interventional

MDR (multidrug resistant) gram-negative bacteria have emerged as an important cause of bloodstream infection in hospitalized patients, especially in immunocompromised hosts. It was previously shown, that intestinal colonization with extended-spectrum β-lactamases (ESBL)-producing or carbapenem-resistant Enterobacteriaceae, carbapenem-resistant A. baumannii and P. aeruginosa) is a clinical predictor of bloodstream infections in patients with haematological malignancies and/or haematopoietic stem cell transplantation [Stoma I. et al., 2016]. To the investigators knowledge no randomized, placebo-controlled clinical trial has been performed to study the efficacy and safety of selective intestinal decolonization strategies in high-risk patients with haematological malignancies. Possible decolonization of MDR gram-negative bacteria in haematological patients could be important for the patient by reducing the risk of infection and for the community by reducing the risk of transmission. The purpose of the proposed study is to assess the efficacy and safety of selective intestinal decolonization of MDR gram-negative bacteria with oral administration of Colistimethate sodium in high risk patients with haematological malignancies.

NCT ID: NCT02810457 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

AVANA
Start date: June 2016
Phase: Phase 3
Study type: Interventional

The purpose of this research study is to compare the effectiveness and safety of FKB238 against Avastin® in men and women with advanced/recurrent non squamous non-small cell lung cancer